Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

about

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma.A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

P2860

Q35797736-17AD8803-7EB5-4233-9560-97961B0BCCBD Q37325007-9978E18A-D573-4206-B48C-6181AA18EF30

P2860

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

Item

http://www.wikidata.org/entity/Q38857256

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

@en

type

Item

label

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

@en

prefLabel

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

@en

P1476

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

@en

P2093

Andrew J Yee

http://www.w3.org/2001/XMLSchema#string

Anuj Mahindra

http://www.w3.org/2001/XMLSchema#string

Darrell Borger

http://www.w3.org/2001/XMLSchema#string

Dianne Finkelstein

http://www.w3.org/2001/XMLSchema#string

Elizabeth O'Donnell

http://www.w3.org/2001/XMLSchema#string

John A Iafrate

http://www.w3.org/2001/XMLSchema#string

Nicole Birrer

http://www.w3.org/2001/XMLSchema#string

Noopur Raje

http://www.w3.org/2001/XMLSchema#string

Nora Horick

http://www.w3.org/2001/XMLSchema#string

Valentina Nardi

http://www.w3.org/2001/XMLSchema#string

P2860

Initial genome sequencing and analysis of multiple myeloma

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

The genetic architecture of multiple myeloma.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.

P304

71-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EBIOM.2014.11.008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275550429

http://www.w3.org/2001/XMLSchema#string

P698

26137536

http://www.w3.org/2001/XMLSchema#string

P932

4485483

http://www.w3.org/2001/XMLSchema#string

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

about

P2860

P2860

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932